Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study
- 24 July 2004
- journal article
- clinical trial
- Published by Springer Nature in Osteoporosis International
- Vol. 16 (1) , 15-25
- https://doi.org/10.1007/s00198-004-1688-0
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Cost effectiveness of raloxifene in the treatment of osteoporosis in SwedenPharmacoEconomics, 2004
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- Association Between Vertebral Fracture and Increased Mortality in Osteoporotic PatientsJournal of Bone and Mineral Research, 2003
- The Brugada NumbersCirculation, 2003
- Cost Effectiveness of Alendronate (Fosamax??) for the Treatment of Osteoporosis and Prevention of FracturesPharmacoEconomics, 2003
- Quantitative Ultrasound and Bone Mineral Density Are Equally Strongly Associated with Risk Factors for OsteoporosisJournal of Bone and Mineral Research, 2001
- Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical SynthesisJournal of Bone and Mineral Research, 2000
- A New Decision Model for Cost-Utility Comparisons of Chemotherapy in Recurrent Metastatic Breast CancerPharmacoEconomics, 1996
- The Cost Effectiveness of Hypertension Treatment in SwedenPharmacoEconomics, 1995
- Bone-density measurementThe Lancet, 1992